“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

References

• ATLAS.ti. Scientific Software Development GmbH. Eden Prairie, MN.
   Google Scholar
• Connell, R. W. 1996. “New Directions in Gender Theory, Masculinity Research, and Gender Politics.” Ethnos 61 (3-4): 157–176. doi:10.1080/00141844.1996.9981534
   Google Scholar
• Cope, M. 2010. “Coding Qualitative Data.” In Qualitative Research Methods in Human Geography, ed. Iain Hay, 223–233. Don Mills, Ont: OUP Canada.
   Google Scholar
• Crowley, J. S., and Bland, S. E. 2018. Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers. Washington, DC: O'Neill Institute/Georgetown Law.
   Google Scholar
• Bonolo, P. F., M. G. Ceccato, G. M. Rocha, F. A. Acurcio, L. N. Campos, and M. D. Guimaraes. 2013. “Gender Differences in Non-Adherence among Brazilian Patients Initiating Antiretroviral Therapy.” Clinics Sao Paulo 68 (5): 612–620. doi:10.6061/clinics/2013(05)06
   PubMed Web of Science ®Google Scholar
• Haberland, N. A. 2015. “The Case for Addressing Gender and Power in Sexuality and HIV Education: A Comprehensive Review of Evaluation Studies.” International Perspectives on Sexual and Reproductive Health 41 (1): 31–42. doi:10.1363/4103115
   PubMed Web of Science ®Google Scholar
• Kabeer, N. 1999. “Resources, Agency, Achievements: Reflections on the Measurement of Women’s Empowerment.” Development and Change 30 (3): 435–464. doi:10.1111/1467-7660.00125
   Web of Science ®Google Scholar
• Kerrigan, D., A. Mantsios, M. Gorgolas, M. L. Montes, F. Pulido, C. Brinson, J. deVente, G. J. Richmond, S. W. Beckham, P. Hammond, et al. 2018. “Experiences with Long Acting Injectable ART: A Qualitative Study among PLHIV Participating in a Phase II Study of Cabotegravir + Rilpivirine (LATTE-2) in the United States and Spain.” PLoS One 13 (1): e0190487. doi:10.1371/journal.pone.0190487
   PubMed Web of Science ®Google Scholar
• Kishor, S. 1997. “Empowermnet of Women in Egypt and Links to the Survival and Health of Their Infants.” Seminar on Female Empowerment and Demographic Processes. Lund, Sweden, April 20–24.
   Google Scholar
• Lazo, M., S. J. Gange, T. E. Wilson, K. Anastos, D. G. Ostrow, M. D. Witt, and L. P. Jacobson. 2007. “Patterns and Predictors ofCchanges in Adherence to Highly Active Antiretroviral Therapy: Longitudinal Study of Men and Women.” Clinical Infectious Diseases 45 (10): 1377–1385. doi:10.1086/522762
   PubMed Web of Science ®Google Scholar
• Lorber, J. 1994. “Night to His Day: The Social Construction of Gender.” In Paradoxes of Gender, 13-55, 32-36. Yale University Press.
   Google Scholar
• Mantsios, A., T. Karver, W. Davis, and D. Kerrigan. (2019). Patient and Provider Perspectives on and Experiences with the Transition from Daily Oral to Long-Acting Injectable Anti-Retroviral Therapy in the United States and Spain. Final Report. London, UK: ViiV Healthcare.
   Google Scholar
• Mantsios, A., M. Murray, T. S. Karver, W. Davis, D. Margolis, P. Kumar, S. Swindells, F. Bredeek, M. Garcia Deltoro, R. Rubio Garcia, et al. 2019. ““I Feel Empowered”: Women’s Perspectives on and Experiences with Long-Acting Injectable anti-Retroviral Therapy in the United States and Spain.” IDWeek, Washington, D.C., Oct 2–6.
   Google Scholar
• Margolis, D. A., C. C. Brinson, G. H. R. Smith, J. de Vente, D. P. Hagins, J. J. Eron, S. K. Griffith, M. H. S. Clair, M. C. Stevens, P. E. Williams, et al. 2015. “Cabotegravir plus Rilpivirine, Once a Day, after Induction with Cabotegravir plus Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral-Naive Adults with HIV-1 Infection (LATTE): A Randomised, Phase 2b, Dose-Ranging Trial.” The Lancet Infectious Diseases 15 (10): 1145–1155. doi:10.1016/S1473-3099(15)00152-8
   PubMed Web of Science ®Google Scholar
• Margolis, D. A., J. Gonzalez-Garcia, H. J. Stellbrink, J. J. Eron, Y. Yazdanpanah, D. Podzamczer, T. Lutz, J. B. Angel, G. J. Richmond, B. Clotet, et al. 2017. “Long-Acting Intramuscular Cabotegravir and Rilpivirine in Adults with HIV-1 Infection (LATTE-2): 96-Week Results of a Randomised, Open-Label, Phase 2b, Non-Inferiority Trial.” The Lancet 390 (10101): 1499–1510. doi:10.1016/S0140-6736(17)31917-7
   PubMed Web of Science ®Google Scholar
• Orkin, C., K. Arastéh, M. G. Hernández-Mora, V. Pokrovsky, E.T. Overton, P.-M. Girard, S. Oka, R. D’Amico, D. Dorey, S. Griffith, et al. 2020. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. New England Journal of Medicine 382 (12): 1124–1135. doi:10.1056/NEJMoa1909512
   Google Scholar
• Ortego, C., T. B. Huedo-Medina, P. Santos, E. Rodriguez, L. Sevilla, M. Warren, and J. Llorca. 2012. “Sex Differences in Adherence to Highly Active Antiretroviral Therapy: A Meta-Analysis.” AIDS Care 24 (12): 1519–1534. doi:10.1080/09540121.2012.672722
   PubMed Web of Science ®Google Scholar
• Panchanadeswaran, S., S. C. Johnson, V. F. Go, A. K. Srikrishnan, S. Sivaram, S. Solomon, M. E. Bentley, and D. Celentano. 2007. “Using the Theory of Gender and Power to Examine Experiences of Partner Violence, Sexual Negotiation, and Risk of HIV/AIDS among Economically Disadvantaged Women in Southern India.” Journal of Aggression, Maltreatment & Trauma 15 (3-4): 155–178. doi:10.1080/10926770802097327
   Google Scholar
• Patton, M. Q. 2002. Qualitative Research and Evaluation Methods. 3rd ed. United States: SAGE.
   Google Scholar
• Pope, C., S. Ziebland, and N. Mays. 2000. “Analysing Qualitative Data.” BMJ 320 (7227): 114–116. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1117368/
   PubMed Web of Science ®Google Scholar
• Puskas, C. M., J. I. Forrest, S. Parashar, K. A. Salters, A. M. Cescon, A. Kaida, C. L. Miller, D. R. Bangsberg, and R. S. Hogg. 2011. “Women and Vulnerability to HAART Non-Adherence: A Literature Review of Treatment Adherence by Gender from 2000 to 2011.” Current HIV/AIDS Reports 8 (4): 277–287. doi:10.1007/s11904-011-0098-0
   PubMedGoogle Scholar
• Rinehart, D. J., A. A. Al-Tayyib, C. Sionean, N. R. Whitesell, S. Dreisbach, and S. Bull. 2018. “Assessing the Theory of Gender and Power: HIV Risk among Heterosexual Minority Dyads.” AIDS & Behavior 22 (6): 1944–1954. doi:10.1007/s10461-017-1983-3
   PubMed Web of Science ®Google Scholar
• Rivero-Méndez, M., C. S. Dawson-Rose, and S. S. Solís-Báez. 2010. “A Qualitative Study of Providers’ Perception of Adherence of Women Living with HIV/AIDS in Puerto Rico.” Qualitative Reports (Online) 15 (2): 232–251. https://www.ncbi.nlm.nih.gov/pubmed/21243076
   PubMedGoogle Scholar
• Roberts, K. J., and T. Mann. 2000. “Barriers to Antiretroviral Medication Adherence in HIV-Infected Women.” AIDS Care 12 (4): 377–386. doi:10.1080/09540120050123774
   PubMed Web of Science ®Google Scholar
• Shelton, R. C., R. E. Goldman, K. M. Emmons, G. Sorensen, and J. D. Allen. 2011. “An Investigation into the Social Context of Low-Income, Urban Black and Latina Women: Implications for Adherence to Recommended Health Behaviors.” Health Education & Behavior 38 (5): 471–481. https://www.ncbi.nlm.nih.gov/pubmed/21856885 doi:10.1177/1090198110382502
   PubMed Web of Science ®Google Scholar
• Swindells, S., J. F. Andrade-Villanueva, G. J. Richmond, G. Rizzardini, A. Baumgarten, M. Masiá, G. Latiff, V. Pokrovsky, F. Bredeek, G. Smith, et al. 2020. “Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.” New England Journal of Medicine 382 (12): 1112–1123. doi:10.1056/NEJMoa1904398
   PubMed Web of Science ®Google Scholar
• Tapp, C., M. J. Milloy, T. Kerr, R. Zhang, S. Guillemi, R. S. Hogg, J. Montaner, and E. Wood. 2011. “Female Gender Predicts Lower Access and Adherence to Antiretroviral Therapy in a Setting of Free Healthcare.” BMC Infectious Diseases 11 (1): 86. doi:10.1186/1471-2334-11-86
   PubMed Web of Science ®Google Scholar
• Weld, E. D., M. S. Rana, R. H. Dallas, A. F. Camacho-Gonzalez, P. Ryscavage, A. H. Gaur, R. Chakraborty, S. Swindells, C. Flexner, and A. L. Agwu. 2019. “Interest of Youth Living with HIV in Long-Acting Antiretrovirals.” Journal of the Acquired Immune Deficiency Syndrome 80 (2): 190–197. 10.1097/qai.0000000000001896
   PubMed Web of Science ®Google Scholar
• Westhoff, C. 2003. “Depot-Medroxyprogesterone Acetate Injection (Depo-Provera): a Highly Effective.Contraceptive Option with Proven Long-Term Safety.” Contraception 68 (2): 75–87. doi:10.1016/S0010-7824(03)00136-7
   PubMed Web of Science ®Google Scholar
• Wingood, G. M., and R. J. DiClemente. 2000. “Application of the Theory of Gender and Power to Examine HI-Related Exposures, Risk Factors, and Effective Interventions for Women.” Health Education & Behavior 27 (5): 539–565. doi:10.1177/109019810002700502
   PubMed Web of Science ®Google Scholar